ELUDE Trademark

Trademark Overview


On Wednesday, June 22, 2022, a trademark application was filed for ELUDE with the United States Patent and Trademark Office. The USPTO has given the ELUDE trademark a serial number of 97471499. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 11, 2025. This trademark is owned by GentiBio, Inc.. The ELUDE trademark is filed in the Treatment & Processing of Materials Services, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Custom manufacture of pharmaceuticals for others; Custom manufacturing of biological cells; consultation in the field of custom manufacture of pharmaceuticals and biological cells

Gene therapy products, namely, engineered cell platforms for immunotherapy purposes; Pharmaceutical preparations for use in the treatment of autoimmune diseases and disorders, autoinflammatory diseases and disorders, alloimmune diseases and disorders and allergic diseases and disorders

Scientific research; Pharmaceutical research; Medical research; Engineering of biological cells; genetic engineering of biological cells; Technological consultation services in the fields of engineering of biological cells; Laboratory research services in the field of immunology and cellular engineering
elude

General Information


Serial Number97471499
Word MarkELUDE
Filing DateWednesday, June 22, 2022
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 11, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 9, 2023

Trademark Statements


Goods and ServicesCustom manufacture of pharmaceuticals for others; Custom manufacturing of biological cells; consultation in the field of custom manufacture of pharmaceuticals and biological cells
Goods and ServicesGene therapy products, namely, engineered cell platforms for immunotherapy purposes; Pharmaceutical preparations for use in the treatment of autoimmune diseases and disorders, autoinflammatory diseases and disorders, alloimmune diseases and disorders and allergic diseases and disorders
Goods and ServicesScientific research; Pharmaceutical research; Medical research; Engineering of biological cells; genetic engineering of biological cells; Technological consultation services in the fields of engineering of biological cells; Laboratory research services in the field of immunology and cellular engineering

Classification Information


International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateMonday, April 3, 2023
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 12, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, April 3, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGentiBio, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Party NameGentiBio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Trademark Events


Event DateEvent Description
Monday, April 3, 2023EXAMINERS AMENDMENT -WRITTEN
Saturday, June 25, 2022NEW APPLICATION ENTERED
Tuesday, July 12, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sunday, April 2, 2023ASSIGNED TO EXAMINER
Monday, April 3, 2023EXAMINERS AMENDMENT E-MAILED
Monday, April 3, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, April 3, 2023EXAMINER'S AMENDMENT ENTERED
Monday, April 3, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, January 4, 2024SOU EXTENSION 1 GRANTED
Wednesday, April 19, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 9, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 9, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 4, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, January 4, 2024SOU TEAS EXTENSION RECEIVED
Thursday, January 4, 2024SOU EXTENSION 1 FILED
Tuesday, July 2, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 3, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 3, 2024SOU EXTENSION 2 FILED
Wednesday, July 3, 2024SOU EXTENSION 2 GRANTED
Friday, December 20, 2024SOU EXTENSION 3 FILED
Saturday, January 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 20, 2024SOU TEAS EXTENSION RECEIVED
Saturday, December 21, 2024SOU EXTENSION 3 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 11, 2025ABANDONMENT - NO USE STATEMENT FILED
Monday, August 11, 2025ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED